Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 25, 2019updated 01 Nov 2021 8:51am

Thermo Fisher to buy Brammer Bio for $1.7bn

Thermo Fisher Scientific has signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.

Thermo Fisher Scientific has signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.

Formed through the merger of Florida Biologix and Brammer Biopharmaceuticals in 2016, Brammer Bio is a contract development and manufacturing organisation (CDMO) owned by Ampersand Capital Partners.

The company is focused on clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

It is also engaged in process and analytical development, and provides regulatory support to large pharmaceutical and biotech firms for the development of new drugs.

Brammer Bio is expected to generate $250m in revenue this year.

Acquisition of the CDMO is intended to bolster Thermo Fisher Scientific’s pharma services business.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Thermo Fisher Scientific president and CEO Marc Casper said: “Gene therapy is an area of increasing focus for our customers and is fast-evolving given its potential to treat a range of genetic disorders.

“The combination of Brammer Bio’s viral vector capabilities with our GMP production expertise and proprietary bioprocessing and cell culture technologies uniquely positions us to partner with our customers to drive the evolution of this incredibly fast-growing market.”

“Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes.”

Brammer Bio employs nearly 600 people at its primary locations in Massachusetts and Florida in the US. The Massachusetts operations include a 66,000ft2 Phase III and commercial CGMP viral vector manufacturing facility and an adjacent 49,000ft2 warehouse and distribution centre.

The company’s 80,000ft2 early clinical campus in Florida comprises three buildings with a process development and analytical development facility.

The Brammer Bio CGMP facility in Florida is intended for viral vector processing to support early phase clinical trials.

Brammer Bio president and CEO Mark Bamforth and chief scientific officer Richard Snyder said: “Brammer Bio has executed more than 100 projects to supply first-in-human gene therapy clinical trials and establish commercial-ready processes, and we’re excited to join Thermo Fisher to take our business to the next level.”

Subject to customary closing conditions, the acquisition is expected to be completed by the second quarter of this year.

After the closing of the deal, Brammer Bio will be integrated into Thermo Fisher’s pharma services business within its Laboratory Products and Services unit.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU